Clinical trials recruiting for Skin Cancer
23
Recruiting trials
31
US states with sites
17
Countries
26%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Ipilimumab | 3 |
| Nivolumab | 3 |
| A novel hGIIA-Vimentin Inhibitor | 1 |
| Alintegimod | 1 |
| Atezolizumab | 1 |
| Brodalumab | 1 |
| Cemiplimab | 1 |
| Cosibelimab | 1 |
| Dose expansion | 1 |
| Everolimus | 1 |
| MDNA11 | 1 |
| ONM-501 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Florida | 5 |
| Massachusetts | 4 |
| Texas | 4 |
| Missouri | 3 |
| California | 2 |
| Colorado | 2 |
| Maryland | 2 |
| New York | 2 |
| Ohio | 2 |
| Arkansas | 1 |
| Connecticut | 1 |
| Georgia | 1 |
Top cities
Boston, Massachusetts 3Houston, Texas 3Canton, Ohio 2St Louis, Missouri 2Aitkin, Minnesota 1Alliance, Ohio 1Atlanta, Georgia 1Aurora, Colorado 1Aurora, Illinois 1Boca Raton, Florida 1
Self-screener
Recruiting trials
- A Beta-only IL-2 ImmunoTherapY Study
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors
- Brodalumab in the Treatment of Immune-Related Adverse Events
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
- Cryoablation+Ipilimumab+Nivolumab in Melanoma
- Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care
- Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
- Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
- High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
- High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
- Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
- Implementation of Teledermoscopy and Artificial Intelligence
- Integrated Cancer Repository for Cancer Research
- Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity
- Multi-modal Quantitative Imaging of the Skin
- Non-invasive Imaging for In-vivo Quantification of Skin Composition and Structure
- Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Rural Adult and Youth Sun Protection Study
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- The Florida ASCENT Study
Related conditions
Trials recruiting for Skin Cancer often also study these conditions. Each links to its own recruiting-trial list.
Melanoma 487Breast cancer 2239Lung cancer 2180Prostate cancer 1234Head and neck cancer 62Colorectal cancer 1359Bladder cancer 59Pancreatic cancer 870Kidney cancer 27Esophageal cancer 65
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Skin Cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.